FindTrial
Sign In

SHR-A1921

DRUG9 trials

Sponsors

Suzhou Suncadia Biopharmaceuticals Co., Ltd., Fudan University, Beijing GoBroad Hospital, Henan Cancer Hospital

Conditions

Advanced Breast CancerAdvanced Salivary Gland CarcinomaAdvanced Solid TumoursBreast CancerBreast NeoplasmBreast TumorsEarly-stage Breast CancerHER2-negative Breast Cancer

Phase 1

A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
NCT05154604
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Advanced Solid Tumours
Start: 2021-12-31End: 2024-08-31Target: 156Updated: 2021-12-13

Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
RecruitingNCT05582499
Fudan UniversityBreast Cancer, Breast Neoplasm, Breast Tumors +7
Start: 2022-11-01End: 2028-09-30Target: 716Updated: 2025-08-22
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
RecruitingNCT05594095
Fudan UniversityAdvanced Breast Cancer, Breast Cancer, Breast Neoplasm +2
Start: 2022-12-30End: 2026-12-01Target: 620Updated: 2024-10-04
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
Active, not recruitingNCT05924256
Fudan UniversityAdvanced Salivary Gland Carcinoma
Start: 2023-07-26End: 2026-12-30Target: 88Updated: 2026-04-02
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Not yet recruitingNCT06433609
Beijing GoBroad HospitalAdvanced Breast Cancer
Start: 2024-06-30End: 2027-11-30Target: 131Updated: 2024-05-30
Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC
Not yet recruitingNCT06465238
Henan Cancer HospitalNSCLC
Start: 2024-06-30End: 2027-06-30Target: 30Updated: 2024-06-20
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
Not yet recruitingNCT06470672
Fudan UniversityAdvanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Start: 2024-12-31End: 2026-07-31Target: 32Updated: 2024-12-20
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
RecruitingNCT06649331
Fudan UniversityAdvanced Breast Cancer, Breast Cancer, HER2-negative Breast Cancer +2
Start: 2024-10-21End: 2027-09-01Target: 160Updated: 2026-03-17

Phase 3

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
RecruitingNCT06394492
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Ovarian Cancer
Start: 2024-05-10End: 2026-12-31Target: 440Updated: 2024-08-09

Related Papers

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
2025-12-04
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.
2025-10-23
Abstract GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial
Clinical Cancer Research2025-06-13
Abstract P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/ HER2- advanced breast cancer: the Linux trial
Clinical Cancer Research2025-06-13
Abstract P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial
Clinical Cancer Research2025-06-13
SHR-A1811 in HER2-expressing salivary gland cancers: Preliminary efficacy and safety results.
Journal of Clinical Oncology2025-05-282 citations
A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing.
Journal of Clinical Oncology2024-06-013 citations
Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial
Therapeutic Advances in Medical Oncology2024-01-017 citations
Abstract LB030: SHR-A1921, a novel TROP-2 ADC with an optimized design and well-balanced profile between efficacy and safety
Cancer Research2023-04-1413 citations
Abstract CT181: A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
Cancer Research2023-04-148 citations